DOI: https://doi.org/10.4414/SMW.2021.w30104
The published manuscript contained a typing error in the chapter ‘Wild-type transthyretin amyloidosis (ATTRwt)’, subchapter ‘Treatment’ (page 13 of the PDF version). It reads: Treatment with tafamidis 61 mg should be considered for patients with cardiac ATTRwt amyloidosis and dyspnea NYHA I-II. [IIa, B].
The correct wording is: Treatment with tafamidis 61 mg should be considered for patients with cardiac ATTRwt amyloidosis and dyspnea NYHA I-III . [IIa, B].
The error occured during manuscript editing and is not in the authors responsability. It has now been corrected online. We apologize to the authors and readers for this error.